5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Biocon Ltd.

•
biocon.comBSE: 532523NSE: BIOCON
Market Cap₹ 63,558 Cr.
Current Price
High / Low₹ 447 / 337
Stock P/E650.5
Book Value₹ 168
Price to Book2.17
Dividend Yield0.13 %
ROCE0.9 %
ROE0.2 %
Face Value₹ 5

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Latest quarter profit grew 728.9% YoY, showing strong momentum
  • Working capital cycle has improved - days down from 70 to 50
  • Institutional investors have been accumulating - FII+DII up 2.6pp
  • Company has a consistent dividend-paying track record

CONS

  • Operating cash flow has been negative in recent years
  • A large part of profit comes from other income (628.2% of PBT)
  • Recent results are weak - TTM profit is down 78.9% versus prior year
  • Promoter holding has decreased over last 2 years: -16.0pp
  • Company has a low return on capital employed of 3.4%
  • Company has a low return on equity of 2.3% over last 3 years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYM150MOMNTM50NIFTY PHARMANIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 100
S.No.Name
1.SUNPHARMA1864.0036.98447236.040.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9405.0085.36249673.200.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4928.4085.95187460.490.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1118.0024.71111520.930.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1380.0033.08111484.470.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1936.0095.67104604.450.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1669.0025.8796030.570.241032.0325.229150.3517.4412.7620.54
8.DRREDDY1140.8029.5595220.280.70435.60-69.108099.80-5.2113.7510.63
9.LUPIN2075.0017.1694882.670.871416.9816.018276.8934.2828.8629.59
10.MANKIND2246.0045.4292769.930.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2417.0037.9468213.700.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.00128.3263558.070.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
513519563533511525563644537583621605624
441452492480466488532582516530548525619
Operating Profit7267715245383162215373795
OPM %14.03%12.96%12.67%9.80%8.79%7.16%5.56%9.63%3.84%9.07%11.80%13.11%0.82%
5664483942746726361134-1223165
Interest4855564055606557566721717
Depreciation30313130303034333334343638
Profit before Tax5046332212160435-886-845770
Tax %6.05%24.57%27.05%35.78%18.18%84.69%3.30%39.43%-9.21%17.27%9.59%11.15%25.32%
Net Profit473524141358421-871-765152
0.390.290.200.120.010.034.884.88-0.070.55-0.570.320.32

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2,5882,4191,7861,9882,0281,7381,9932,1272,2432,3462,434
1,9962,1061,5761,7061,7171,6771,9721,9122,0802,1212,223
Operating Profit5913132102823116121216163225211
OPM %22.85%12.95%11.75%14.18%15.34%3.52%1.04%10.14%7.25%9.61%8.65%
991303083661521873,137254863105108
Interest41310070199237142104
Depreciation1511369298104108117121128137142
Profit before Tax5363064235483591402,97115066151128
Tax %3.15%22.01%10.57%20.41%21.82%38.37%4.13%20.63%7.81%27.06%23.97%
Net Profit519238378436280862,8481196093798
EPS8.764.024.143.712.340.7223.820.995.080.23—
Dividend Payout %11.55%25.16%15.86%0.00%0.00%69.73%6.32%50.32%9.85%217.86%—

COMPOUNDED SALES GROWTH

10 Years:
0%
5 Years:
3%
3 Years:
6%

COMPOUNDED PROFIT GROWTH

10 Years:
-20%
5 Years:
-33%
3 Years:
-76%

STOCK PRICE CAGR

10 Years:
10%
5 Years:
2%
3 Years:
13%
1 Year:
7%

RETURN ON EQUITY

10 Years:
7%
5 Years:
8%
3 Years:
2%
Last Year:
0%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2017

Jun 15

2:1

Audited Financial Results for the quarter and year ended March 31, 2017.

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital100300300600600600600600600810
6,3976,3896,7566,8547,2057,39910,20710,23210,81626,157
26120521239961601,3902,1362,8791,133
Trade Payables450580644521372381457448814589
155151126117154209352345511581
Total Liabilities7,3647,6258,0388,1318,4278,74913,00713,76115,62129,271
8948591,0597217298058999001,0601,331
Capital Work in Progress241318254152165270329545687523
3,8884,1994,0934,9535,4135,2809,2719,31811,38324,978
540562802535431542560665836875
00000001,0488291,003
Cash & Bank38319735637560168972058625092
1,4181,4901,4741,3961,0891,1631,228698577469
Total Assets7,3647,6258,0388,1318,4278,74913,00713,76115,62129,271

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
30644324647863376260-123624-180
Cash from Investing110-556311-213-711-306-1,178-296-992-6,582
Cash from Financing-238-55-208-129281121,0393444956,602
58-25521245-112-14681-76127-160

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
60.6460.6460.6460.6454.4554.4554.4544.9144.68
5.905.935.665.676.046.617.397.528.14
14.2914.4415.3615.7322.8322.0621.6724.0123.33
Government0.000.000.000.000.000.000.000.000.00
19.1718.9918.3417.9716.6816.8316.4523.4923.80

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-09
General Updates

2026-09-09 - Biocon Limited has informed the Exchange about Communication regarding remittance of final dividend for the FY 2025-26

2026-09-08
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-08 - Biocon Limited has informed the Exchange about Schedule of meet

2026-09-08
Press Release

2026-09-08 - Biocon Limited has informed the Exchange regarding a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".

2026-08-31
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-31 - Biocon Limited has informed the Exchange about Schedule of meet

2026-08-28
General Updates

2026-08-28 - Biocon Limited has informed the Exchange about "Communication regarding remittance of final dividend for the FY 2025-26"

2026-08-25
Updates

2026-08-25 - Biocon Limited has informed the Exchange regarding 'Company Statement'.

2026-08-18
Updates

2026-08-18 - Biocon Limited has informed the Exchange regarding 'Company Statement'.

2026-08-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-11 - Biocon Limited has informed the Exchange about Schedule of meet

2026-08-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-11 - Biocon Limited has informed the Exchange about Transcript

News

Recent coverage and analyst commentary for BIOCON

Loading news…

🤖

AI Stock Analyst

Biocon Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login